Ascendis Pharma A/S
ASND- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001612042
In the last 90 days, Ascendis Pharma A/S insiders filed 1 open-market purchase and 2 sales; 313 institutions reported holding it in 13F filings for Q2 2026, worth $17.8B in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Ascendis Pharma A/S as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 189
- +6 vs. Q4 2023
- Shares held
- 60.8M
- +1.26M (+2.1%) vs. Q4 2023
- Total value
- $9.19B
- +$1.69B (+22.6%) vs. Q4 2023
- New holders
- 39
- 74 more added
- Sold out
- 33
- 50 more reduced
2 institutions that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ASND on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 313 | $17.8B |
| Q1 2026 | 274 | $14.3B |
| Q4 2025 | 303 | $13.8B |
| Q3 2025 | 281 | $12.7B |
| Q2 2025 | 248 | $10.9B |
| Q1 2025 | 245 | $10.1B |
| Q4 2024 | 215 | $8.78B |
| Q3 2024 | 220 | $9.31B |
| Q2 2024 | 203 | $8.28B |
| Q1 2024 | 189 | $9.19B |
| Q4 2023 | 185 | $7.59B |
| Q3 2023 | 160 | $5.64B |
| Q2 2023 | 158 | $5.45B |
| Q1 2023 | 164 | $6.54B |
| Q4 2022 | 187 | $8.05B |
| Q3 2022 | 183 | $6.89B |
| Q2 2022 | 168 | $5.88B |
| Q1 2022 | 177 | $7.27B |
| Q4 2021 | 172 | $7.85B |
| Q3 2021 | 166 | $9.24B |
| Q2 2021 | 171 | $7.24B |
| Q1 2021 | 177 | $6.83B |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Ascendis Pharma A/S; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −6,500−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −6,300−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −5,881−100.0% | Sold out |
| Sequoia Financial Advisors, LLC | 0 | $0 | 0.00% | −5,811−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −5,808−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −5,561−100.0% | Sold out |
| CenterBook Partners LP | 0 | $0 | 0.00% | −5,207−100.0% | Sold out |
| GTS Securities LLC | 0 | $0 | 0.00% | −4,316−100.0% | Sold out |
| Campbell & CO Investment Adviser LLC | 0 | $0 | 0.00% | −3,997−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −3,681−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −3,217−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −2,986−100.0% | Sold out |
| Wedbush Securities Inc | 0 | $0 | 0.00% | −2,413−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −2,270−100.0% | Sold out |
| Camden Capital, LLC | 0 | $0 | 0.00% | −2,144−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −2,002−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −145−100.0% | Sold out |
| Headlands Technologies LLC | 0 | $0 | 0.00% | −121−100.0% | Sold out |
| Cullen/Frost Bankers, Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Able Wealth Management LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Putnam Investments LLC | – | – | – | – | Not filed |
| Coppell Advisory Solutions LLC | – | – | – | – | Not filed |